Research Site

Shumen 9700

2 studies enrolling now · 14 studies all time

What they study most

Active Cutaneous Lupus Erythematosus, Anemia, Breast Cancer, Breast Cancer, Early Breast Cancer, Breast Neoplasms, Dialysis-Dependent Chronic Kidney Disease, ER-Positive HER2-Negative Breast Cancer, Gastric Cancer, Heart Failure, Metastatic Breast Cancer, Neoplasms, Hormone-Dependent, Non Small Cell Lung Carcinoma NSCLC

Studies at this site

• Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin — Recruiting now
• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) — Recruiting now
• Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) — Running, not enrolling
• A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer — Running, not enrolling
• A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease — Running, not enrolling
• Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE) — Completed
• Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD) — Completed
• Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure — Stopped early
• Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer — Completed
• Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis. — Completed
• A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer — Completed
• First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma — Stopped early
• Assessment of Efficacy and Safety in Relieving Opioid-induced Constipation in Patients With Cancer-related Pain — Stopped early
• The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer — Stopped early